{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T12:24:31Z","timestamp":1770035071766,"version":"3.49.0"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.bcp.2017.03.022","type":"journal-article","created":{"date-parts":[[2017,4,2]],"date-time":"2017-04-02T14:30:19Z","timestamp":1491143419000},"page":"32-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Hydroxyurea inhibits parvovirus B19 replication in erythroid progenitor cells"],"prefix":"10.1016","volume":"136","author":[{"given":"Francesca","family":"Bonvicini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gloria","family":"Bua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Conti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Manaresi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Gallinella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2017.03.022_b0005","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s00705-013-1914-1","article-title":"The family Parvoviridae","volume":"159","author":"Cotmore","year":"2014","journal-title":"Arch. Virol."},{"key":"10.1016\/j.bcp.2017.03.022_b0010","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1056\/NEJMra030840","article-title":"Parvovirus B19","volume":"350","author":"Young","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2017.03.022_b0015","doi-asserted-by":"crossref","DOI":"10.5402\/2013\/898730","article-title":"Parvovirus B19 achievements and challenges","author":"Gallinella","year":"2013","journal-title":"ISRN Virol."},{"issue":"1","key":"10.1016\/j.bcp.2017.03.022_b0020","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1128\/CMR.00040-16","article-title":"Human parvoviruses","volume":"30","author":"Qiu","year":"2017","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.bcp.2017.03.022_b0025","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1053\/beha.1999.0071","article-title":"Haematological consequences of parvovirus B19 infection","volume":"13","author":"Brown","year":"2000","journal-title":"Baillieres Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.bcp.2017.03.022_b0030","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/rmv.395","article-title":"Parvovirus B19 and the pathogenesis of anaemia","volume":"13","author":"Chisaka","year":"2003","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.bcp.2017.03.022_b0035","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1182\/blood-2003-01-0069","article-title":"Epidemiology of human parvovirus B19 in children with sickle cell disease","volume":"103","author":"Smith-Whitley","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2017.03.022_b0040","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/tme.12168","article-title":"Profound sustained reticulocytopenia and anaemia in an adult patient with sickle cell disease","volume":"24","author":"Win","year":"2014","journal-title":"Transfusion Med."},{"key":"10.1016\/j.bcp.2017.03.022_b0045","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/jmv.24378","article-title":"Prevalence and incidence of erythrovirus B19 infection in children with sickle cell disease: the impact of viral infection in acute clinical events","volume":"88","author":"Brito Silva Furtado","year":"2016","journal-title":"J. Med. Virol."},{"issue":"3","key":"10.1016\/j.bcp.2017.03.022_b0050","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/(SICI)1096-8652(199603)51:3<207::AID-AJH5>3.0.CO;2-0","article-title":"Sickle cell acute chest syndrome associated with parvovirus B19 infection: case series and review","volume":"51","author":"Lowenthal","year":"1996","journal-title":"AJH"},{"issue":"3","key":"10.1016\/j.bcp.2017.03.022_b0055","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/pbc.22035","article-title":"Simultaneous acute splenic sequestration and acute aplastic crisis in children with sickle cell disease","volume":"53","author":"Yates","year":"2009","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.bcp.2017.03.022_b0060","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.blre.2013.12.002","article-title":"Greaves p, Amos RJ. Bone marrow necrosis and fat embolism syndrome in sickle cell disease: increased susceptibility of patients with non-SS genotypes and a possible association with human parvovirus B19 infection","volume":"28","author":"Tsitsikas","year":"2014","journal-title":"Blood Rev."},{"key":"10.1016\/j.bcp.2017.03.022_b0065","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1159\/000362812","article-title":"Intrauterine blood transfusion current indications and associated risks","volume":"36","author":"Lindenburg","year":"2014","journal-title":"Fetal Diagn. Ther."},{"key":"10.1016\/j.bcp.2017.03.022_b0070","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/cid\/cis1046","article-title":"Intravenous immunoglobulin therapy for pure red cell aplasia related to human parvovirus B19 infection: a retrospective study of 10 patients and review of the literature","volume":"56","author":"Crabol","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.bcp.2017.03.022_b0075","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jcv.2014.11.021","article-title":"Paradoxical response to intravenous immunoglobulin in a case of Parvovirus B19-associated chronic fatigue syndrome","volume":"62","author":"Attard","year":"2015","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.bcp.2017.03.022_b0080","doi-asserted-by":"crossref","first-page":"D158","DOI":"10.1093\/nar\/gkw1099","article-title":"UniProt: the universal protein knowledgebase","volume":"45","author":"The UniProt Consortium","year":"2017","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"10.1016\/j.bcp.2017.03.022_b0085","doi-asserted-by":"crossref","first-page":"e0148547","DOI":"10.1371\/journal.pone.0148547","article-title":"Parvovirus B19 replication and expression in differentiating erythroid progenitor cells","volume":"11","author":"Bua","year":"2016","journal-title":"PLoS ONE"},{"issue":"6","key":"10.1016\/j.bcp.2017.03.022_b0090","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1128\/JVI.71.6.4517-4521.1997","article-title":"Experimental infection of cynomolgus monkeys with simian parvovirus B19","volume":"71","author":"O\u2019Sullivan","year":"1997","journal-title":"J. Virol."},{"key":"10.1016\/j.bcp.2017.03.022_b0095","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1128\/JVI.69.6.3897-3899.1995","article-title":"Human parvovirus B19 can infect cynomolgus monkey marrow cells in tissue culture","volume":"69","author":"Gallinella","year":"1995","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.bcp.2017.03.022_b0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2006.10.006","article-title":"The acyclic nucleoside phosphonates from inception to clinical use: historical perspective","volume":"75","author":"De Clercq","year":"2007","journal-title":"Antiviral Res."},{"issue":"7","key":"10.1016\/j.bcp.2017.03.022_b0105","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.bcp.2006.09.014","article-title":"Acyclic nucleoside phosphonates: past, present and future \u2013 bridging chemistry to HIV, HBV, HCV, HPV, adeno-, herpes-, and poxvirus infections: the phosphonate bridge","volume":"73","author":"De Clercq","year":"2007","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2017.03.022_b0110","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.antiviral.2014.11.004","article-title":"Antiviral effect of cidofovir on parvovirus B19 replication","volume":"113","author":"Bonvicini","year":"2015","journal-title":"Antiviral Res."},{"key":"10.1016\/j.bcp.2017.03.022_b0115","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.virusres.2016.04.002","article-title":"Enhanced inhibition of parvovirus B19 replication by cidofovir in extendedly exposed erythroid progenitor cells","volume":"220","author":"Bonvicini","year":"2016","journal-title":"Virus Res."},{"issue":"6","key":"10.1016\/j.bcp.2017.03.022_b0120","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1517\/13543776.15.6.659","article-title":"Ribonucleotide reductase: target therapy for human disease","volume":"15","author":"Gallicchio","year":"2005","journal-title":"Expert Opin. Ther. Patents"},{"issue":"12","key":"10.1016\/j.bcp.2017.03.022_b0125","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1128\/AAC.43.12.2885","article-title":"Hydroxyurea potentiates the antiherpesvirus activities of purine and pyrimidine nucleoside and nucleoside phosphonate analogs","volume":"43","author":"Neyts","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.bcp.2017.03.022_b0130","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.antiviral.2013.07.016","article-title":"Ribonucleotide reductase inhibitors hydroxyurea, didox, and trimidox inhibit human cytomegalovirus replication in vitro and synergize with ganciclovir","volume":"100","author":"Bhave","year":"2013","journal-title":"Antiviral Res."},{"key":"10.1016\/j.bcp.2017.03.022_b0135","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.bcp.2016.01.003","article-title":"Inhibition of hepatitis B virus replication by targeting ribonucleotide reductase M2 protein","volume":"103","author":"Liu","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2017.03.022_b0140","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1097\/01.aids.0000176217.02743.d1","article-title":"Optimal suppression of HIV replication by low-dose hydroxyurea through the combination of antiviral and cytostatic (\u2018virostatic\u2019) mechanisms","volume":"19","author":"Loria","year":"2005","journal-title":"AIDS"},{"issue":"10","key":"10.1016\/j.bcp.2017.03.022_b0145","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/jama.2014.10517","article-title":"Management of sickle cell disease summary of the 2014 evidence-based report by expert panel members","volume":"312","author":"Yan","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.bcp.2017.03.022_b0150","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/MOH.0000000000000282","article-title":"Allogeneic stem cell transplantation for sickle cell disease","volume":"23","author":"Robinson","year":"2016","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.bcp.2017.03.022_b0155","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","article-title":"Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia","volume":"332","author":"Charache","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2017.03.022_b0160","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood-2004-12-4973","article-title":"Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study","volume":"106","author":"Hankins","year":"2005","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.bcp.2017.03.022_b0165","doi-asserted-by":"crossref","first-page":"3850","DOI":"10.1182\/blood-2014-08-435768","article-title":"Update on the use of hydroxyurea therapy in sickle cell disease","volume":"124","author":"Wong","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2017.03.022_b0170","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1542\/peds.2008-0441","article-title":"Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children","volume":"122","author":"Strouse","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.bcp.2017.03.022_b0175","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1038\/pr.2013.227","article-title":"Emerging science of hydroxyurea therapy for pediatric sickle cell disease","volume":"75","author":"Green","year":"2014","journal-title":"Pediatr. Res."},{"issue":"11","key":"10.1016\/j.bcp.2017.03.022_b0180","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1128\/JCM.01970-13","article-title":"Keeping pace with parvovirus B19 genetic variability: a multiplex genotype-specific quantitative PCR assay","volume":"51","author":"Bonvicini","year":"2013","journal-title":"J. Clin. Microbiol."},{"issue":"2","key":"10.1016\/j.bcp.2017.03.022_b0185","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.virol.2008.09.002","article-title":"Functional analysis and quantitative determination of the expression profile of human parvovirus B19","volume":"381","author":"Bonvicini","year":"2008","journal-title":"Virology"},{"key":"10.1016\/j.bcp.2017.03.022_b0190","article-title":"Monograph on the potential human reproductive and developmental effects of hydroxyurea","author":"NTP-CERHR","year":"2008","journal-title":"NIH Publication"},{"issue":"23","key":"10.1016\/j.bcp.2017.03.022_b0195","doi-asserted-by":"crossref","first-page":"12766","DOI":"10.1128\/JVI.02333-13","article-title":"Human parvovirus B19 infection causes cell cycle arrest of human erythroid progenitors at late s phase that favors viral DNA replication","volume":"87","author":"Luo","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.bcp.2017.03.022_b0200","first-page":"1","article-title":"Parvovirus B19 infection in children with sickle cell disease in the hydroxyurea era","author":"Hankins","year":"2016","journal-title":"Exp. Biol. Med."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295217301843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295217301843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,4]],"date-time":"2020-10-04T21:03:00Z","timestamp":1601845380000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295217301843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":40,"alternative-id":["S0006295217301843"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2017.03.022","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hydroxyurea inhibits parvovirus B19 replication in erythroid progenitor cells","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2017.03.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}